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Background 
   Current strategies to guide the selection of neo-adjuvant or adjuvant therapy in esophageal and gastric 
adenocarcinomas (EAC/GAC) are inadequate.  We assessed a clinically validated 44 gene DNA Damage 
Response Deficiency (DDRD) assay to predict prognosis following neo-adjuvant DNA damaging chemotherapy 
(CT) in EAC and adjuvant CT or chemo-radiotherapy (CRT) in GAC.  
Methods 
   Transcriptional profiling of 273 formalin fixed paraffin embedded pre-treatment endoscopic EAC biopsies was 
performed using the Almac Diagnostics XcelTM array.  All EAC patients were treated with cisplatin-based neo-
adjuvant chemotherapy followed by surgical resection between 2003 and 2014 at four UK centers in the 
OCCAMS consortium.  Further validation was performed using a publically available dataset of 270 resected 
gastric cancers treated with adjuvant platinum-based CT, CRT or surgery alone at the Samsung Medical 
Centre, Seoul, Korea.  The association between the DDRD score and prognosis was assessed by Kaplan-
Meier analysis and Cox Proportional Hazards regression. 
Results 
   A total of 66 EAC samples (24%) were characterized as DDRD positive with the remaining 207 samples 
(76%) being DDRD negative.  DDRD assay positivity was associated with improved DFS (HR 0.58; 95% CI 
0.36-0.93; p=0.024) and OS (HR 0.56; 95% CI 0.34-0.92; p= 0.023) following multivariate analysis.  DDRD 
positive patients had a higher pathological response rate (p= 0.033) and a higher rate of loco-regional versus 
distant relapse (30% vs 20%; p= 0.013). 
   For GAC, 132 samples (49%) were characterized as DDRD positive with the remaining 138 (51%) being 
DDRD negative.  DDRD positivity was associated with improved DFS (HR 0.48; 95% CI 0.25-0.96; p=0.037) 
following D2 gastrectomy and adjuvant CT or CRT.  DDRD status was not associated with DFS in the surgery 
alone cohort (HR 0.87; 95% CI 0.55-1.38; p=0.562). 
Conclusion 
  The DDRD assay is strongly predictive of benefit from DNA damaging neo-adjuvant CT and esophagectomy 
in EAC and gastrectomy and CT/CRT in GAC and can be applied to routine diagnostic material. 
 
 
